Lung Cancer, Sexual Dysfunction
Conditions
Keywords
Lung Cancer, Sexual Dysfunction
Brief summary
The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.
Detailed description
It is planned to develop a study with a larger number of patients with lung cancer, including the population of Spain and Latin American countries to obtain a sample of more diverse and heterogeneous characteristics, with clinical, cultural, and sociodemographic differences. This will make it possible to obtain better and greater data and therefore define the clinical and treatment factors significantly associated with DS in these individuals and obtain a more complete vision of the reality of the problem. The results of this research will make it possible to carry out interventions specifically directed at this population and to modify the oncological follow-up guidelines currently in force. Likewise, the information collected will serve as the basis for generating new protocols for a multidisciplinary approach, including the participation of psychology and specialists in urology, gynecology, and psychiatry. The general objective of this observational study is identify and describe the type, frequency, and severity of sexual dysfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. The recruitment will be carried out from July 2023 and will be carried out until December 2023, the analysis of the information will be carried out from January to March 2024.
Interventions
DRUGSystemic oncological treatment
Oncological systemic treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months
Sponsors
Fundación GECP
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Age greater than or equal to 18 years and less than or equal to 70 years. * Diagnosis of lung cancer stages IB to IV. * Having received systemic oncological treatment for at least 3 months or being in oncological follow-up after having received systemic treatment for a minimum of 3 months with stable tumor disease or partial or complete response in images. * ECOG ≤ 2
Exclusion criteria
* Patients with comorbidities (renal failure, cardiovascular diseases or similar) not controlled with corresponding medical management. * Individuals with physical disability or cognitive impairment that prevents them from completing the electronic data collection form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Different Type, Frequency and Severity of Sexual Dysfunction | From inclusion up to 3 months | Identify and describe the type, frequency, and severity of sexual disfunction in patients with lung cancer and generate strategies for clinical management and oncological follow-up directed and based on the specific findings in this population. |
Countries
Argentina, Colombia, Peru, Portugal, Spain
Contacts
STUDY_CHAIRAylen Vanessa Ospina Serrano, MD
Hospital Puerta del Hierro Investigator
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 60.44 years STANDARD_DEVIATION 7.29 |
| Region of Enrollment Argentina | 14 Participants |
| Region of Enrollment Colombia | 18 Participants |
| Region of Enrollment Portugal | 8 Participants |
| Region of Enrollment Spain | 408 Participants |
| Sex: Female, Male Female | 171 Participants |
| Sex: Female, Male Male | 277 Participants |
| Smoking status Former smoker | 114 Participants |
| Smoking status Never smoker | 75 Participants |
| Smoking status Smoker | 256 Participants |
| Smoking status Unknown | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 0 |
| other Total, other adverse events | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 |
Outcome results
None listed